WallStreetZenWallStreetZen

NASDAQ: APDN
Applied Dna Sciences Inc Stock Forecast, Predictions & Price Target

Analyst price target for APDN

Based on 1 analyst offering 12 month price targets for Applied Dna Sciences Inc.
Min Forecast
$2.00+455.56%
Avg Forecast
$2.00+455.56%
Max Forecast
$2.00+455.56%

Should I buy or sell APDN stock?

Based on 1 analyst offering ratings for Applied Dna Sciences Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their APDN stock forecasts and price targets.

APDN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-12-08

1 of 1

Forecast return on equity

Is APDN forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
36.1%

Forecast return on assets

Is APDN forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

APDN revenue forecast

What is APDN's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$3.9M-56.2%
Avg 2 year Forecast
$7.1M-21.63%
APDN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

APDN revenue growth forecast

How is APDN forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
4.14%
Industry
6.35%
Market
10.3%
APDN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
APDN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

APDN vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
APDN$0.36$2.00+455.56%Buy
MDXH$2.35$7.50+219.15%Strong Buy
XWEL$1.37$7.00+410.95%Buy
NDRA$0.26N/AN/A
PRPO$6.74N/AN/A

Applied Dna Sciences Stock Forecast FAQ

Is Applied Dna Sciences Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: APDN) stock is to Buy APDN stock.

Out of 1 analyst, 0 (0%) are recommending APDN as a Strong Buy, 1 (100%) are recommending APDN as a Buy, 0 (0%) are recommending APDN as a Hold, 0 (0%) are recommending APDN as a Sell, and 0 (0%) are recommending APDN as a Strong Sell.

If you're new to stock investing, here's how to buy Applied Dna Sciences stock.

What is APDN's revenue growth forecast for 2024-2025?

(NASDAQ: APDN) Applied Dna Sciences's forecast annual revenue growth rate of 4.14% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 6.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.3%.

Applied Dna Sciences's revenue in 2024 is $8,995,855.On average, 1 Wall Street analysts forecast APDN's revenue for 2024 to be $66,896,090, with the lowest APDN revenue forecast at $66,896,090, and the highest APDN revenue forecast at $66,896,090.

In 2025, APDN is forecast to generate $119,699,856 in revenue, with the lowest revenue forecast at $119,699,856 and the highest revenue forecast at $119,699,856.

What is APDN's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: APDN) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of N/A.

What is APDN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year APDN price target, the average APDN price target is $2.00, with the highest APDN stock price forecast at $2.00 and the lowest APDN stock price forecast at $2.00.

The Wall Street analyst predicted that Applied Dna Sciences's share price could reach $2.00 by Dec 8, 2024. The average Applied Dna Sciences stock price prediction forecasts a potential upside of 455.56% from the current APDN share price of $0.36.

What is APDN's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: APDN) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.